Underlying malignancies can cause rebleeding after negative angiography

Acute non-variceal gastrointestinal bleeding accounts for approximately 20% of emergency room visits and 5% of admissions. Although endoscopy has been used as a first-line treatment option in patients with gastrointestinal bleeding, angiographic intervention can be used as a safe diagnostic and treatment method in patients with gastrointestinal bleeding that is refractory to endoscopic treatment. The incidence of rebleeding in patients with negative initial angiography has been reported in up to 60% of cases. However, little is known about the predictive factors for rebleeding.

A research article to be published on August 28, 2009 in the World Journal of Gastroenterology addresses this question. A research team led by Hyo-Cheol Kim from Seoul National University Hospital, Korea, identified the possible predictive factors for rebleeding after negative angiographic findings in patients with acute non-variceal gastrointestinal bleeding.

One hundred and twenty eight patients with acute non-variceal gastrointestinal bleeding had negative findings after initial angiography. Clinical and laboratory parameters were analyzed retrospectively.

They found that clinical factors including underlying malignancy, liver cirrhosis, and hematemesis are important predictors for rebleeding after angiographically negative findings in patients with acute non-variceal gastrointestinal bleeding.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how omega-3 and omega-6 fatty acids may impact cancer rates